by Ariana | Mar 28, 2025 | Article
How to Access Benlysta SC for Lupus Nephritis in Ontario Benlysta SC Now Available Under Ontario Drug Benefit Effective Date: February 28, 2025 Discover how the inclusion of Benlysta SC in the Ontario Drug Benefit Program marks a significant advancement for lupus...
by Ariana | Mar 28, 2025 | Article
Let’s Talk Lupus: Conversations with Macenzie Each month, Let’s Talk Lupus: Conversations with Macenzie brings you inspiring stories from Canadians living with lupus. Through these interviews, Macenzie, a Toronto-based journalist and writer diagnosed with...
by Ariana | Mar 27, 2025 | Article
How Anifrolumab Helps Reduce Organ Damage in Lupus Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can cause widespread inflammation and irreversible organ damage. Managing SLE effectively requires controlling disease activity, preventing...
by Ariana | Mar 27, 2025 | Article
Learn how the TULIP trials demonstrated that anifrolumab significantly improves rates of lupus low disease activity state (LLDAS) and remission in SLE patients. Anifrolumab is one of the only two biologic treatments approved for patients with moderate to severe SLE....
by Ariana | Mar 27, 2025 | Article
Arielle Mendel, MD, M.Sc., Junior Scientist, RI-MUHC, Montreal General Hospital site Assistant Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University Department of Medicine, Division of Rheumatology, MUHC Study: REcombinant...
by Ariana | Mar 27, 2025 | Article
Advocating for Lupus Research in Canada Why Advocacy Matters for Canada’s Lupus Community Despite advances in lupus treatments, there are notable gaps that require attention and improvement in Canada. Learn More The Importance of Advocacy Driving Change for Lupus...
